5 Most Undervalued Blue Chip Stocks to Invest In

2. Becton, Dickinson and Company (NYSE:BDX)

On March 23, 2026, Argus lowered the price target on Becton, Dickinson and Company (NYSE:BDX) to $180 from $230 and maintained a Buy rating, citing the company’s transition toward a pure-play medtech model following the spin-off of its Biosciences and Diagnostics Solutions business. Argus also noted the stock trades at about 11.5 times forward earnings, below the 20.4 times average for its MedTech coverage universe.

Earlier in the month, Becton, Dickinson and Company (NYSE:BDX) announced it received FDA 510(k) clearance for Surgiphor 1000mL, described as the first 1000 mL antimicrobial irrigation system designed for powered lavage, aimed at improving surgical efficiency and safety.

Last month, the company reported Q1 adjusted EPS of $2.91, above the $2.81 consensus estimate, on revenue of $5.3B versus $5.15B expected. CEO Tom Polen said results reflected “stronger-than-expected” performance driven by execution and growth across key markets, adding that the company is “fully pivoting to New BD” following its portfolio changes, with a focus on innovation, productivity, and long-term growth.

Becton, Dickinson and Company (NYSE:BDX) develops and sells medical devices, laboratory equipment, and diagnostic products globally.